Immunological Tolerance Induced by Nanoliposome with Autoantigenie Peptide and Artesunate to Inhibit Complement and Remodel Immune Balance for Multiple Sclerosis Treatment
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202403774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Yaya Wei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia, China. Hauptthemen laut MEDLINE: Multiple Sclerosis, Liposomes, Immune Tolerance, Autoantigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Natural Science Foundation of Ningxia Province, Technology Innovation leading talents in Ningxia Province.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a demyelinating autoimmune disease (AD) accompanied by immune disorders and complement over activation. Although re‐instatement of immune balance does alleviate MS symptoms, exploration of concomitant complement inhibition for neuron protection has not been evaluated. Herein, we developed myelin oligodendrocyte glycoprotein 35‐55 (MOG) peptide and artemisinin (ART) co‐loaded liposomes (MOG‐ART‐Lip) to simultaneously restore immune balance and inhibit complement activation. This nanoplatform enhanced solubility of both components while enabling CNS delivery. Liposomes loaded with MOG would induce tolerogenic DCs (tol‐DCs) that express low‐levels of costimulatory molecules, capable of antigenic peptide presentation and induction of regulatory T cells, while ART shifted microglia from pro‐inflammatory (M1) to anti‐inflammatory (M2) phenotypes. Importantly, ART suppressed complement‐mediated demyelination via the C3/C3a receptor (C3aR) pathway. In vivo studies showed MOG‐ART‐Lip significantly reduced neuroinflammation, attenuated demyelination, and promoted neural repair, leading to functional recovery. Overall, results of this study suggest that a combination of an auto‐antigenic peptide and an immune‐modulator provides a promising modality for the treatment of MS by re‐establishing antigen‐specific immune tolerance. As such, the results of the study provide valuable insight into a new approach for development of combinatorial complement therapies for the treatment of MS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia, China.
- School of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China.
- Department of Pharmaceutical Preparation, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
ORCID-Profile: Jianhong Yang
Förderung
- Natural Science Foundation of Ningxia Province
- Technology Innovation leading talents in Ningxia Province
Zitieren
APA
Wei, Y., Li, L., Fu, T., Gao, T., Ma, L., Zuo, W., & Yang, J. (2025). Immunological Tolerance Induced by Nanoliposome with Autoantigenie Peptide and Artesunate to Inhibit Complement and Remodel Immune Balance for Multiple Sclerosis Treatment. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202403774
Vancouver
Wei Y, Li L, Fu T, Gao T, Ma L, Zuo W, et al. Immunological Tolerance Induced by Nanoliposome with Autoantigenie Peptide and Artesunate to Inhibit Complement and Remodel Immune Balance for Multiple Sclerosis Treatment. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202403774
BibTeX
@article{Wei2025,
author = {Wei, Yaya and Li, Li and Fu, Tingting and Gao, Ting and Ma, Lanlan and Zuo, Wenbao and Yang, Jianhong},
title = {Immunological Tolerance Induced by Nanoliposome with Autoantigenie Peptide and Artesunate to Inhibit Complement and Remodel Immune Balance for Multiple Sclerosis Treatment},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202403774}
}
EUVIMED